Gastroschisis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Gastroschisis Market Outlook
Thelansis’s “Gastroschisis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Gastroschisis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Gastroschisis Overview
Gastroschisis
is a congenital anomaly characterized by a full-thickness defect in the
abdominal wall near the umbilicus, allowing the protrusion of the intestines.
It is uncommonly associated with genetic disorders. Unlike other similar
conditions, the exposed bowel in gastroschisis lacks a protective membrane,
leading to adhesion, dilation, and inflammation of the intestines. Infants with
this condition often experience restricted intrauterine growth. Diagnosis is
typically made during a 20-week ultrasound when freely floating bowel loops are
observed within the uterus. Pregnancies affected by gastroschisis show elevated
maternal serum alpha-fetoprotein (AFP) levels. In contrast to other prenatal
abdominal wall defects such as omphalocele, only a small percentage (10%) of
gastroschisis cases are accompanied by malformations outside the
gastrointestinal tract. Infants with gastroschisis can be categorized as either
simple or complex, which helps determine their prognosis and guide their care.
The complexity classification is based on the presence or absence of
complications like intestinal atresia, stenosis, perforation, necrosis,
malrotation, or volvulus. The exact cause of gastroschisis is not fully
understood. It arises due to a failure in the development and formation of the
ventral body wall during embryogenesis, leading to the herniation of the
intestines. Several factors have been implicated in the development of
gastroschisis, including tobacco use, specific environmental exposures (such as
nitrosamines and atrazine), the use of cyclooxygenase inhibitors (such as
aspirin and ibuprofen), and certain decongestants (such as pseudoephedrine and
phenylpropanolamine). The formation of the abdominal wall occurs during the
fourth week of gestation, progressing in the craniocaudal and mediolateral
directions. In the sixth week, the liver and midgut herniate through the
umbilical cord, followed by the midgut returning to the abdominal cavity by the
tenth week after completing the rotation. It generally has a more favorable
prognosis, with excellent long-term outcomes, compared to other abdominal wall
defects. The overall survival rate for live-born infants with gastroschisis is
98 percent. Infants with gastroschisis are more likely to be born prematurely
(28% compared to 6% in unaffected infants). Complications can arise in infants
with gastroschisis due to the need for total parenteral nutrition (TPN) and the
associated risk of line sepsis, the configuration of the bowel leading to
necrotizing enterocolitis (NEC), and infections of the abdominal wound
resulting from gastroschisis closure.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment